Infinity Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Seth Tasker

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	7.7yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	6yrs

Recente managementupdates

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Jun 03

Recent updates

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Nov 10

Infinity Pharmaceuticals: Waiting For A Deal

Sep 08

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

May 23

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Dec 29

Investigating Infinity Pharmaceuticals

Nov 25

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Jul 18

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Jun 03

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Apr 13

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Feb 19

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Jan 15

Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer

Jan 06

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Dec 11

Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium

Dec 09

Infinity Pharmaceutical Reaching Vital New Staging Posts

Dec 01

Analyse CEO-vergoeding

Hoe is Seth Tasker's beloning veranderd ten opzichte van Infinity Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	-US$41m
Mar 31 2023	n/a	n/a	-US$43m
Dec 31 2022	n/a	n/a	-US$44m
Sep 30 2022	n/a	n/a	-US$47m
Jun 30 2022	n/a	n/a	-US$47m
Mar 31 2022	n/a	n/a	-US$46m
Dec 31 2021	n/a	n/a	-US$45m
Sep 30 2021	n/a	n/a	-US$44m
Jun 30 2021	n/a	n/a	-US$43m
Mar 31 2021	n/a	n/a	-US$41m
Dec 31 2020	US$1m	US$386k	-US$40m
Sep 30 2020	n/a	n/a	-US$41m
Jun 30 2020	n/a	n/a	-US$43m
Mar 31 2020	n/a	n/a	-US$44m
Dec 31 2019	US$653k	US$368k	-US$47m
Sep 30 2019	n/a	n/a	-US$44m
Jun 30 2019	n/a	n/a	-US$19m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	n/a	n/a	-US$11m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$31m
Mar 31 2018	n/a	n/a	-US$41m
Dec 31 2017	US$1m	US$320k	-US$42m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Seth redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.

Compensatie versus inkomsten: De vergoeding van Seth is gestegen terwijl het bedrijf verliesgevend is.

CEO

Seth Tasker (44 yo)

7.7yrs

Tenure

US$1,435,444

Compensatie

Mr. Seth A. Tasker, J.D., has been Senior Vice President, General Counsel and Secretary at Infinity Pharmaceuticals, Inc. since December 2019 and has been its CEO since September 1, 2023 and had been its C...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Anthony Evnin	Independent Director	17.5yrs	US$93.08k	0.24% $ 0.2
Norman Selby	Lead Independent Director	12yrs	US$125.82k	0.017% $ 0.01
David Beier	Independent Director	5.9yrs	US$85.58k	0.0097% $ 0.009
Roy Steven Herbst	Member of Scientific Advisory Board	6yrs	geen gegevens	geen gegevens
David Munn	Member of Scientific Advisory Board	6yrs	geen gegevens	geen gegevens
F. Hodi	Member of Scientific Advisory Board	6yrs	geen gegevens	geen gegevens
Richard B. Gaynor	Independent Director	4yrs	US$83.08k	0% $ 0
Dmitry Gabrilovich	Member of Scientific Advisory Board	6yrs	geen gegevens	geen gegevens
Jeffery Kutok	Chairman of Scientific Advisory Board	4yrs	US$759.67k	geen gegevens
Samuel Agresta	Chair of Clinical Advisory Board	no data	US$73.08k	0.012% $ 0.01
Toni Choueiri	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Michael Postow	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

71yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van INFI.Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 6 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/03/11 09:08
Aandelenkoers aan het einde van de dag	2024/03/11 00:00
Inkomsten	2023/06/30
Jaarlijkse inkomsten	2022/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Infinity Pharmaceuticals, Inc. wordt gevolgd door 26 analisten. van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Christopher Raymond	Baird
Andrew D'Silva	B. Riley Securities, Inc.
Jason Kantor	Credit Suisse

Infinity Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Infinity Pharmaceuticals, Inc. Announces Resignation of Samuel Agresta, Sujay R. Kango and Brian Schwartz from Board

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Recent updates

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Infinity Pharmaceuticals Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum MVPHS Requirement

Rosen Law Firm Announces the Filing of A Class Action Lawsuit on Behalf of Purchasers of Securities of Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals, Inc. Announces Resignation of Samuel Agresta, Sujay R. Kango and Brian Schwartz from Board

MEI Pharma, Inc. (NasdaqCM:MEIP) cancelled the acquisition of Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI) from The Vanguard Group, Inc. and others.

New major risk - Revenue and earnings growth

Infinity Pharmaceuticals, Inc. Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck

Infinity Pharmaceuticals Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 20% to US$4.00

Infinity Pharmaceuticals Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Requirement

Consensus revenue estimates increase by 276%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Infinity Pharmaceuticals: Waiting For A Deal

Consensus estimates of losses per share improve by 10%

Infinity Pharmaceuticals, Inc. Unveils New Positive Data from the Phase 2 MARIO-275 Clinical Trial

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 20%

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$6.67

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Consensus revenue estimates increase by 232%

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Price target decreased to US$9.00

Infinity Pharmaceuticals, Inc. Provides Earning Guidance for 2022

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Price target increased to US$9.71

Infinity Pharmaceuticals, Inc. Announces Encouraging Updated Data from Phase 2 Mario-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium

Investigating Infinity Pharmaceuticals

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2020)

Consensus revenue estimates increase to US$1.89m

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.17 loss in 2Q 2020)

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Consensus forecasts updated

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 1Q 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.83 loss in FY 2019)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2021

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Infinity Pharmaceuticals, Inc. Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at Asco Genitourinary Cancers Symposium

New 90-day high: US$5.36

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

New 90-day high: US$2.80

Infinity Pharmaceuticals, Inc. Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer

Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer

Infinity Pharmaceuticals, Inc. Announces Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium

New 90-day high: US$2.16

Infinity Pharmaceutical Reaching Vital New Staging Posts

Analysts update estimates

New 90-day high: US$1.51

Revenue and earnings beat expectations

Third quarter 2020 earnings released: US$0.16 loss per share

Infinity Pharmaceuticals, Inc. Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer (SITC)